Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.
Sherborne AL., Hosking FJ., Prasad RB., Kumar R., Koehler R., Vijayakrishnan J., Papaemmanuil E., Bartram CR., Stanulla M., Schrappe M., Gast A., Dobbins SE., Ma Y., Sheridan E., Taylor M., Kinsey SE., Lightfoot T., Roman E., Irving JAE., Allan JM., Moorman AV., Harrison CJ., Tomlinson IP., Richards S., Zimmermann M., Szalai C., Semsei AF., Erdelyi DJ., Krajinovic M., Sinnett D., Healy J., Gonzalez Neira A., Kawamata N., Ogawa S., Koeffler HP., Hemminki K., Greaves M., Houlston RS.
Using data from a genome-wide association study of 907 individuals with childhood acute lymphoblastic leukemia (cases) and 2,398 controls and with validation in samples totaling 2,386 cases and 2,419 controls, we have shown that common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 x 10(-11)), irrespective of cell lineage.